Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07MOX
|
|||
| Former ID |
DAP000016
|
|||
| Drug Name |
Norepinephrine
|
|||
| Synonyms |
norepinephrine; L-Noradrenaline; Levarterenol; 51-41-2; L-Norepinephrine; Levophed; (-)-Norepinephrine; L-arterenol; (R)-Noradrenaline; (R)-Norepinephrine; Levonor; Levonorepinephrine; Adrenor; Aktamin; Levonoradrenaline; Sympathin E; (R)-(-)-Norepinephrine; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; Noradrenalin; Norepirenamine; norepinephrinum; Noradrenalinum; Levoarterenol; Norartrinal; Nor-Epirenan; L-3,4-dihydroxyphenylethanolamine; Levarterenolo; Noreinefrina; Norepinefrina; Norepinephrinum; Levarterenolo [DCIT]; Nor adrenalin; Noradrenalina [Italian]; Norepinephrine Noradrenalin; LT03330026; ALBB-006229; Nor adrenalin (TN); Noradrenaline (JP15); Noreinefrina [INN-Spanish]; Norepinephrine (INN); Norepinephrine [INN:JAN]; Norepinephrinum [INN-Latin]; Norepinephrine l-Tartrate (1:1); D-(-)-Noradrenaline; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; (-)-(R)-Norepinephrine; (-)-Arterenol free base; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI); 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Ecteinascidins
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sepsis [ICD-11: 1G40-1G41] | Approved | [1], [2] | |
| Therapeutic Class |
Vasoconstrictor Agents
|
|||
| Company |
Bedford Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H11NO3
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1C(CN)O)O)O
|
|||
| InChI |
1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1
|
|||
| InChIKey |
SFLSHLFXELFNJZ-QMMMGPOBSA-N
|
|||
| CAS Number |
CAS 51-41-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3828, 840952, 841792, 7847144, 7980168, 8144526, 8149447, 10298272, 11335405, 11360644, 11363903, 11366465, 11369027, 11371679, 11373774, 11377189, 11461616, 11484784, 11488880, 11490336, 11491893, 11494823, 15898897, 22426371, 24714977, 24891196, 26512253, 26611841, 26679364, 26683762, 26754493, 26754494, 29215339, 36883508, 46394455, 46506201, 47291023, 47662149, 47959614, 48034990, 48259106, 48416337, 49892614, 50109852, 50109853, 51036046, 53788371, 56311831, 56313397, 57288371
|
|||
| ChEBI ID |
CHEBI:18357
|
|||
| ADReCS Drug ID | BADD_D01583 ; BADD_D01584 | |||
| SuperDrug ATC ID |
C01CA03
|
|||
| SuperDrug CAS ID |
cas=000051412
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Stimulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 505). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040455. | |||
| REF 3 | Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.